Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.

A number of new treatment options for different stages of bladder cancer are on the horizon, which will make education about the data behind these therapies and how they might be used in clinical practice important. Of interest, a number of treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer (NMIBC) are currently being evaluated in clinical trials, and systemic therapy options for muscle-invasive and metastatic disease have rapidly expanded.

These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with urothelial carcinoma.

In order to help patients make informed treatment decisions, health care professionals need to understand the clinical data regarding the indications and efficacy of novel therapies.

With many new indications for immune checkpoint inhibitors in urothelial bladder cancer, as well as a number of important ongoing trials using these agents, timely education on this topic is important.

In order to help patients make informed treatment decisions, health care professionals need to understand the clinical data regarding the indications and efficacy of novel therapies.

With an increasing number of treatment options for both non–muscle invasive bladder cancer (NMIBC) and advanced urothelial bladder cancer available, it is important for physicians to understand these various treatments and identify which option is likely to bring the greatest benefit to a specific patient.